Research Fellow Reid Shaw is focused on identifying targeted and less-toxic drugs that work synergistically with current treatments to prevent single-agent resistance and increase the progression-free survival. Reid’s interdisciplinary research strategy has identified two drug combinations that preferentially kill cancer cells while preserving the viability of normal cells.

Cure First raised funds to drive the research of high-throughput technologies and screening to precisely identify characteristics of the cancerous tissue and pinpoint therapies specific to individual neuroblastoma (NB) patients. In the past 2 years, thanks to generous donations, we have continued to meet our goals and push forward the next generation of healthcare.

Barbara Shaffer was known to her friends as Janie, but her husband and family called her "Sweetheart." She fought ovarian cancer for more than a decade. Her life, and the love she shared with everyone around her, inspired Cure First to establish Project Sweetheart, a research initiative named in her honor.

On January 21, 2016, Cure First brought together prominent experts from a variety of disciplines—clinical oncology, computational sciences, patient advocacy, pharmaceutical R&D, cancer research, and genetics—to share their work and vision about the realities and possibilities of new cancer therapies.